Goldman Sachs’s Amicus Therapeutics FOLD Stock Holding History

Goldman Sachs’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-18,700	Closed	-$432K	–	6163
2020 Q4	$432K	Buy	+18,700	New	+$382K	﹤0.01%	4692
2018 Q1	–	Sell	-250,000	Closed	-$3.6M	–	6051
2017 Q4	$3.6M	Sell	250,000 -252,200	-50%	-$3.46M	﹤0.01%	3300
2017 Q3	$7.57M	Buy	+502,200	New	+$6.64M	﹤0.01%	2795
2016 Q3	–	Sell	-46,800	Closed	-$256K	–	7065
2016 Q2	$256K	Sell	46,800 -98,600	-68%	-$690K	﹤0.01%	5478
2016 Q1	$1.23M	Sell	145,400 -6,000	-4%	-$42.5K	﹤0.01%	3916
2015 Q4	$1.47M	Buy	+151,400	New	+$1.36M	﹤0.01%	3920
2015 Q3	–	Sell	-60,000	Closed	-$849K	–	7346
2015 Q2	$849K	Sell	60,000 -68,400	-53%	-$822K	﹤0.01%	4684
2015 Q1	$1.4M	Buy	+128,400	New	+$1.13M	﹤0.01%	4140
2014 Q4	–	Sell	-44,200	Closed	-$263K	–	7173
2014 Q3	$263K	Buy	+44,200	New	+$232K	﹤0.01%	5886
2013 Q4	–	Sell	-44,100	Closed	-$102K	–	6692
2013 Q3	$102K	Hold	44,100	–	–	﹤0.01%	6147
2013 Q2	$103K	Buy	+44,100	New	+$136K	﹤0.01%	5864

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Goldman Sachs's FOLD Position: Q1 2026 in Review

Goldman Sachs increased its Amicus Therapeutics (FOLD) stake by 88% in Q1 2026, buying an estimated $77.6M and bringing the position to 11,556,008 shares worth $167M. The position accounts for 0.02% of the portfolio, ranked #762.

Goldman Sachs first reported a position in FOLD in Q2 2013 and has held it in 52 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Goldman Sachs held 11,556,008 shares of Amicus Therapeutics worth $167M as of Q1 2026.
Goldman Sachs bought 5,413,052 Amicus Therapeutics shares in Q1 2026, an estimated $77.6M.
Amicus Therapeutics made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #762 holding.
Goldman Sachs first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 52 quarters since.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.